NIH: Alzheimer's Clinical Trials Consortium (ACTC) (U24)RFA-AG-17-005
This Funding Opportunity Announcement (FOA) invites applications to establish an Alzheimer's disease Clinical Trials Consortium (ACTC) that will run trials focused on interventions that may prevent, delay, or treat the symptoms of Alzheimer's disease (AD) and other age related dementias. The ACTC will include multiple clinical trials sites and trial coordination and management infrastructure. A separate FOA will solicit applications for clinical trials to be managed and supported by the ACTC.
The ACTC will conduct clinical trials (Phase I to III) of promising pharmacological and non- pharmacological interventions for cognitive and neuropsychiatric symptoms in individuals with AD and other age related dementias across the spectrum from pre-symptomatic to more severe stages of disease. The ACTC will provide a state-of-the-art clinical trial infrastructure to facilitate rapid development and implementation of protocols. The ACTC will also provide leadership to the field in innovative trial design methods, outcomes and analyses as well as recruitment strategies, particularly in diverse populations.
USC may only submit one application in response to this program announcement. Your application submission MUST be coordinated with the Office of the Vice President for Research. Please send a two page abstract via email to Richard White (
NIH indicates that a Letter of Intent is REQUIRED by January 2, 2017, and a full proposal by February 2, 2017. For more information: http://grants.nih.gov/grants/guide/rfa-files/RFA-AG-17-005.html